AP2014007980A0 - Heterobicyclic compounds as beta-lactamase inhibitors - Google Patents

Heterobicyclic compounds as beta-lactamase inhibitors

Info

Publication number: AP2014007980A0
Authority: AP; ARIPO
Prior art keywords: beta; lactamase inhibitors; heterobicyclic compounds; heterobicyclic; compounds
Prior art date: 2012-04-02

Application number

AP2014007980A

Other languages

English (en)

Inventor

Hui Xiong

Brendan Chen

Janelle Comita-Prevor

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-02

Filing date

2013-04-02

Publication date

2014-10-31

2013-04-02 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2014-10-31 Publication of AP2014007980A0 publication Critical patent/AP2014007980A0/xx

Links

239000003781 beta lactamase inhibitor Substances 0.000 title 1
229940126813 beta-lactamase inhibitor Drugs 0.000 title 1
125000002618 bicyclic heterocycle group Chemical group 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AP2014007980A 2012-04-02 2013-04-02 Heterobicyclic compounds as beta-lactamase inhibitors AP2014007980A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261618993P	2012-04-02	2012-04-02
PCT/GB2013/050869 WO2013150296A1 (en)	2012-04-02	2013-04-02	Heterobicyclic compounds as beta-lactamase inhibitors

Publications (1)

Publication Number	Publication Date
AP2014007980A0 true AP2014007980A0 (en)	2014-10-31

Family

ID=48083562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2014007980A AP2014007980A0 (en)	2012-04-02	2013-04-02	Heterobicyclic compounds as beta-lactamase inhibitors

Country Status (41)

Country	Link
US (2)	US9309245B2 (de)
EP (1)	EP2834239B1 (de)
JP (1)	JP6122484B2 (de)
KR (1)	KR102042867B1 (de)
CN (1)	CN104364254B (de)
AP (1)	AP2014007980A0 (de)
AR (1)	AR090539A1 (de)
AU (1)	AU2013245399B2 (de)
BR (1)	BR112014024279B1 (de)
CA (1)	CA2866467C (de)
CL (1)	CL2014002589A1 (de)
CO (1)	CO7071137A2 (de)
CR (1)	CR20140428A (de)
CY (1)	CY1120269T1 (de)
DK (1)	DK2834239T3 (de)
DO (1)	DOP2014000212A (de)
ES (1)	ES2663416T3 (de)
HR (1)	HRP20180450T1 (de)
HU (1)	HUE036722T2 (de)
IL (1)	IL234660A (de)
IN (1)	IN2014MN01882A (de)
LT (1)	LT2834239T (de)
MA (1)	MA37383A1 (de)
ME (1)	ME03031B (de)
MX (1)	MX354627B (de)
MY (1)	MY176969A (de)
NO (1)	NO2935238T3 (de)
NZ (1)	NZ630259A (de)
PE (1)	PE20142403A1 (de)
PH (1)	PH12014502224B1 (de)
PL (1)	PL2834239T3 (de)
PT (1)	PT2834239T (de)
RS (1)	RS56966B1 (de)
RU (1)	RU2645678C2 (de)
SG (1)	SG11201405965RA (de)
SI (1)	SI2834239T1 (de)
SM (1)	SMT201800142T1 (de)
TN (1)	TN2014000417A1 (de)
TW (1)	TWI597281B (de)
UY (1)	UY34723A (de)
WO (1)	WO2013150296A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR090539A1 (es)	2012-04-02	2014-11-19	Astrazeneca Ab	COMPUESTOS INHIBIDORES DE b LACTAMASA
BR112017010132B1 (pt) *	2014-11-17	2023-02-14	Entasis Therapeutics Limited	Combinações e seus usos no tratamento de infecções bacterianas resistentes
WO2016156344A1 (en)	2015-03-31	2016-10-06	Mutabilis	Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3075733A1 (de) *	2015-03-31	2016-10-05	Mutabilis	Neuartige heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
WO2016156348A1 (en)	2015-03-31	2016-10-06	Mutabilis	Novel heterocyclic compounds and their use in preventing or treating bacterial infections
EP3075381A1 (de) *	2015-04-03	2016-10-05	Mutabilis	Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
RU2714197C2 (ru) *	2015-04-03	2020-02-13	Мутабилис	Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций
CN107580595B (zh) *	2015-05-07	2020-09-18	拜欧蒂姆公司	杂环化合物及它们在预防或治疗细菌感染中的应用
EP3091018A1 (de) *	2015-05-07	2016-11-09	Mutabilis	Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
CA3000087A1 (en)	2015-10-02	2017-04-06	Legochem Biosciences, Inc.	Compositions and methods for inhibiting beta-lactamase
EP3184529A1 (de) *	2015-12-23	2017-06-28	Mutabilis	Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
WO2017203266A1 (en)	2016-05-25	2017-11-30	Entasis Therapeutics Limited	Combination therapy for treatment of resistant bacterial infections
CA3036557A1 (en) *	2016-09-16	2018-03-22	Entasis Therapeutics Limited	Beta-lactamase inhibitor compounds
JOP20190061A1 (ar)	2016-09-28	2019-03-26	Novartis Ag	مثبطات بيتا-لاكتاماز
EP3301094A1 (de) *	2016-09-30	2018-04-04	Mutabilis	Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
EP3300736B1 (de)	2016-09-30	2021-05-05	Mutabilis	Zusammensetzung mit einer antibiotischen verbindung und heterocyclischen verbindung und deren verwendung bei der vorbeugung oder behandlung bakterieller infektionen
EA037916B1 (ru) *	2017-02-08	2021-06-07	Энтасис Терапеутикс Лимитед	Соединения-ингибиторы бета-лактамаз
PL3630111T3 (pl) *	2017-05-08	2022-05-23	Entasis Therapeutics, Inc.	Związki i sposoby leczenia zakażeń bakteryjnych
US10085999B1 (en) *	2017-05-10	2018-10-02	Arixa Pharmaceuticals, Inc.	Beta-lactamase inhibitors and uses thereof
US11497731B2 (en)	2018-05-14	2022-11-15	National University Corporation Tokai National Higher Education And Research System	β-lactamase inhibitor
US11905286B2 (en)	2018-08-09	2024-02-20	Antabio Sas	Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3608318A1 (de) *	2018-08-09	2020-02-12	Antabio SAS	Diaazabicyclooctanone derivate als antibiotika
KR102790878B1 (ko) *	2018-08-09	2025-04-02	앤타바이오 에스에이에스	세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논
RU2739761C2 (ru) *	2018-09-27	2020-12-28	Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук	Способ получения n-алкил-n-{ [3-алкил-3,8-диазабицикло[3.2.1]окта-1(7),5-диен-8-ил]метил} аминов и их применение в качестве средств с антимикробной активностью
CN111196808B (zh) *	2018-11-16	2022-10-18	南京圣和药业股份有限公司	二氮杂双环类化合物及其应用
CN110615790A (zh) *	2019-10-24	2019-12-27	北京融英医药科技有限公司	一种利格列汀制备工艺的改进方法
US20220194791A1 (en) *	2020-12-22	2022-06-23	Tokyo Ohka Kogyo Co., Ltd.	Method for producing aqueous solution of purified orthoperiodic acid, method for producing semiconductor device, and aqueous solution of orthoperiodic acid
EP4281042A1 (de) *	2021-01-20	2023-11-29	Entasis Therapeutics Limited	Antibiotische zusammensetzungen mit fester dosierung
CN113979981B (zh) *	2021-10-22	2023-04-07	天津医科大学	一种巯基响应型脱碱基位点捕获试剂及应用
WO2023206580A1 (en)	2022-04-29	2023-11-02	Entasis Therapeutics Limited	Durlobactam crystalline forms
CN118271319B (zh) *	2022-12-30	2025-02-28	成都四面体药物研究有限公司	一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
WO2024227071A1 (en)	2023-04-26	2024-10-31	Entasis Therapeutics Limited	Synthesis of durlobactam
CN116693531A (zh) *	2023-06-09	2023-09-05	河南师范大学	一种桥联多环内酰胺类化合物的合成方法
CN119998293A (zh)	2023-08-08	2025-05-13	成都四面体药物研究有限公司	一种含脲三环的β-内酰胺酶抑制剂、其制备方法及其用途
WO2025106662A1 (en)	2023-11-15	2025-05-22	Entasis Therapeutics, Inc.	Preparation of boronic acid intermediates useful for the preparation of compounds for treating bacterial infections
WO2025239896A1 (en)	2024-05-16	2025-11-20	Entasis Therapeutics, Inc.	Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of acinetobacter baumannii-calcoaceticus complex

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ274915A (en) *	1993-12-29	1997-11-24	Pfizer	N-(hetero)aryl methyl diazabicycloalkane derivatives
FR2812635B1 (fr) *	2000-08-01	2002-10-11	Aventis Pharma Sa	Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) *	2002-01-28	2006-10-20	Aventis Pharma Sa	Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en)	2002-12-06	2008-10-21	Novexel	Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr)	2007-04-12	2013-06-14	Novexel	Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
MY162532A (en)	2008-01-18	2017-06-15	Merck Sharp & Dohme	Beta-lactamase inhibitors
FR2930553B1 (fr)	2008-04-29	2010-05-21	Novexel	Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (de) *	2008-06-19	2017-12-27	Astra Zeneca Holding France	Verwendung von (1r,2s,5r)-1,6-diazabicyclo [3.2.1]oktan-2-carboxamid, 7-oxo-6-(sulfooxy)-, mononatriumsalz als diagnostisches reagens zum nachweis von serin-beta-lactamasen
FR2936798B1 (fr) *	2008-10-03	2012-09-28	Novexel	Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr)	2008-10-10	2010-12-03	Novexel	Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr)	2008-10-10	2012-11-23	Novexel	Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr)	2009-10-09	2011-04-15	Novexel	Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
KR101512738B1 (ko)	2011-08-27	2015-04-17	욱크하르트 리미티드	1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
KR101618424B1 (ko)	2011-08-30	2016-05-04	욱크하르트 리미티드	1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
BR112014003476A2 (pt)	2011-09-13	2017-03-01	Wockhardt Ltd	compostos contendo nitrogênio e seu uso
US8796257B2 (en)	2011-12-02	2014-08-05	Naeja Pharmaceutical Inc.	Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
KR20140144254A (ko)	2012-03-30	2014-12-18	큐비스트 파마슈티컬즈 인코포레이티드	1,3,4-옥사디아졸 및 1,3,4-티아디아졸 β-락타마제 억제제
US8969570B2 (en)	2012-03-30	2015-03-03	Cubist Pharmaceuticals, Inc.	Beta-lactamase inhibitors
MX2014011825A (es)	2012-03-30	2015-02-20	Cubist Pharm Inc	INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
US8916709B2 (en)	2012-03-30	2014-12-23	Cubist Pharmaceuticals, Inc.	1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es)	2012-04-02	2014-11-19	Astrazeneca Ab	COMPUESTOS INHIBIDORES DE b LACTAMASA
AR091222A1 (es)	2012-05-30	2015-01-21	Meiji Seika Pharma Co Ltd	INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
CA2881169C (en)	2012-08-25	2020-06-16	Wockhardt Limited	1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
WO2014141132A1 (en)	2013-03-14	2014-09-18	Naeja Pharmaceutical Inc.	NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

2013
- 2013-03-27 AR ARP130101024A patent/AR090539A1/es active IP Right Grant
- 2013-04-02 SG SG11201405965RA patent/SG11201405965RA/en unknown
- 2013-04-02 IN IN1882MUN2014 patent/IN2014MN01882A/en unknown
- 2013-04-02 MX MX2014011351A patent/MX354627B/es active IP Right Grant
- 2013-04-02 ME MEP-2018-72A patent/ME03031B/de unknown
- 2013-04-02 JP JP2015503939A patent/JP6122484B2/ja active Active
- 2013-04-02 ES ES13715426.6T patent/ES2663416T3/es active Active
- 2013-04-02 UY UY0001034723A patent/UY34723A/es active IP Right Grant
- 2013-04-02 BR BR112014024279-8A patent/BR112014024279B1/pt active IP Right Grant
- 2013-04-02 RU RU2014141579A patent/RU2645678C2/ru active
- 2013-04-02 KR KR1020147030338A patent/KR102042867B1/ko active Active
- 2013-04-02 CN CN201380028869.0A patent/CN104364254B/zh active Active
- 2013-04-02 US US14/389,854 patent/US9309245B2/en active Active
- 2013-04-02 PT PT137154266T patent/PT2834239T/pt unknown
- 2013-04-02 NZ NZ630259A patent/NZ630259A/en unknown
- 2013-04-02 MY MYPI2014702879A patent/MY176969A/en unknown
- 2013-04-02 AU AU2013245399A patent/AU2013245399B2/en active Active
- 2013-04-02 AP AP2014007980A patent/AP2014007980A0/xx unknown
- 2013-04-02 EP EP13715426.6A patent/EP2834239B1/de active Active
- 2013-04-02 HR HRP20180450TT patent/HRP20180450T1/hr unknown
- 2013-04-02 SI SI201330969T patent/SI2834239T1/en unknown
- 2013-04-02 SM SM20180142T patent/SMT201800142T1/it unknown
- 2013-04-02 DK DK13715426.6T patent/DK2834239T3/en active
- 2013-04-02 MA MA37383A patent/MA37383A1/fr unknown
- 2013-04-02 WO PCT/GB2013/050869 patent/WO2013150296A1/en not_active Ceased
- 2013-04-02 PE PE2014001432A patent/PE20142403A1/es not_active Application Discontinuation
- 2013-04-02 RS RS20180294A patent/RS56966B1/sr unknown
- 2013-04-02 PL PL13715426T patent/PL2834239T3/pl unknown
- 2013-04-02 TW TW102111953A patent/TWI597281B/zh active
- 2013-04-02 CA CA2866467A patent/CA2866467C/en active Active
- 2013-04-02 HU HUE13715426A patent/HUE036722T2/hu unknown
- 2013-04-02 LT LTEP13715426.6T patent/LT2834239T/lt unknown
- 2013-12-05 NO NO13817739A patent/NO2935238T3/no unknown
2014
- 2014-09-15 IL IL234660A patent/IL234660A/en active IP Right Grant
- 2014-09-15 DO DO2014000212A patent/DOP2014000212A/es unknown
- 2014-09-17 CO CO14206256A patent/CO7071137A2/es unknown
- 2014-09-19 CR CR20140428A patent/CR20140428A/es unknown
- 2014-09-26 CL CL2014002589A patent/CL2014002589A1/es unknown
- 2014-10-02 PH PH12014502224A patent/PH12014502224B1/en unknown
- 2014-10-02 TN TN2014000417A patent/TN2014000417A1/fr unknown
2016
- 2016-02-29 US US15/056,090 patent/US9623014B2/en active Active
2018
- 2018-03-14 CY CY20181100311T patent/CY1120269T1/el unknown

Also Published As

Publication number	Publication date
JP6122484B2 (ja)	2017-04-26
BR112014024279B1 (pt)	2021-09-08
ES2663416T3 (es)	2018-04-12
BR112014024279A2 (de)	2017-06-20
EP2834239A1 (de)	2015-02-11
ME03031B (de)	2018-10-20
SI2834239T1 (en)	2018-05-31
CA2866467A1 (en)	2013-10-10
AR090539A1 (es)	2014-11-19
IL234660A (en)	2017-08-31
NZ630259A (en)	2016-06-24
LT2834239T (lt)	2018-03-26
KR20140140625A (ko)	2014-12-09
AU2013245399A1 (en)	2014-10-02
CL2014002589A1 (es)	2015-01-30
HK1207071A1 (en)	2016-01-22
CY1120269T1 (el)	2019-07-10
CO7071137A2 (es)	2014-09-30
MX2014011351A (es)	2014-12-05
PT2834239T (pt)	2018-03-23
AU2013245399B2 (en)	2016-04-21
MA37383A1 (fr)	2016-06-30
RS56966B1 (sr)	2018-05-31
TN2014000417A1 (en)	2016-03-30
UY34723A (es)	2015-07-31
PL2834239T3 (pl)	2018-06-29
DOP2014000212A (es)	2014-10-31
TWI597281B (zh)	2017-09-01
BR112014024279A8 (pt)	2018-04-03
RU2645678C2 (ru)	2018-02-27
US20160175290A1 (en)	2016-06-23
IN2014MN01882A (de)	2015-07-10
DK2834239T3 (en)	2018-03-26
TW201345907A (zh)	2013-11-16
JP2015512440A (ja)	2015-04-27
PH12014502224B1 (en)	2017-11-08
SG11201405965RA (en)	2014-10-30
SMT201800142T1 (it)	2018-05-02
CN104364254A (zh)	2015-02-18
CR20140428A (es)	2015-01-12
KR102042867B1 (ko)	2019-11-08
US9623014B2 (en)	2017-04-18
RU2014141579A (ru)	2016-05-27
MX354627B (es)	2018-03-14
US9309245B2 (en)	2016-04-12
HUE036722T2 (hu)	2018-07-30
CA2866467C (en)	2020-03-24
HRP20180450T1 (hr)	2018-06-01
US20150073011A1 (en)	2015-03-12
EP2834239B1 (de)	2017-12-27
CN104364254B (zh)	2017-02-22
NO2935238T3 (de)	2018-05-26
MY176969A (en)	2020-08-28
WO2013150296A1 (en)	2013-10-10
PH12014502224A1 (en)	2015-01-12
PE20142403A1 (es)	2015-01-23

Publication	Publication Date	Title
IL289834A (en)	2022-03-01	Conversion of tricyclic compounds as fgfr inhibitors
SG11201405965RA (en)	2014-10-30	Heterobicyclic compounds as beta-lactamase inhibitors
ZA201504200B (en)	2017-09-27	Beta-lactamase inhibitors
IL239457A0 (en)	2015-07-30	Novel heterocyclic compounds as bromodomain inhibitors
LT2892889T (lt)	2017-12-11	Inhibitoriaus junginiai
AP2015008591A0 (en)	2013-07-31	Heterocyclic compounds
IL239153A0 (en)	2015-07-30	Substitute pyridopyrazine as an inhibitor
EP2847186A4 (de)	2015-10-28	Als kinasehemmer verwendbare substituierte aminochinazoline
GB201211019D0 (en)	2012-08-01	Inhibitor compounds